Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448838 · ClinicalTrials.gov registry record · NA
Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A NA study, sponsored by University of Miami.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT00448838 is a NA study that has completed, run by University of Miami. The registered enrollment target is 42 participants.
The verdict
NCT00448838, a NA study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy may kill more tumor cells. PURPOSE: This clinical trial is studying how well giving cetuximab together with gemcitabine and oxaliplatin works in treating patients with locally advanced or metastatic pancreatic cancer.
Interventions
- BIOLOGICAL Cetuximab
- DRUG Oxaliplatin
- DRUG Gemcitabine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00448838
The ClinicalTrials.gov registry entry for NCT00448838 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT00448838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00448838 about?
NCT00448838 is a clinical study titled "Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of pancreatic cancer by bl...
What is the current status of trial NCT00448838?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2006-05. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00448838?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Oxaliplatin (DRUG), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00448838?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.